Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA

Transgene , a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the oncolytic virus BT-001 in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a Phase I/IIa clinical trial for the treatment of patients with solid tumors.

Top Artificial Intelligence InsightsDetermining the Potential of Your AI Algorithm Starts with Measurement

Under the terms of the supply agreement, MSD will provide pembrolizumab to be used in combination with BT-001 in the ongoing Phase I/IIa clinical trial.

“By combining BT-001 with the anti-PD-1 drug KEYTRUDA we expect to optimize the patient’s immune response to induce a strong and effective anti-tumor response. This agreement will allow us to move further on the clinical development of our promising co-developed oncolytic candidate BT-001” said Hedi Ben Brahim, CEO of Transgene.

AI and ML NewsWhy SMBs Shouldn’t Be Afraid of Artificial Intelligence (AI)

Related Posts
1 of 40,354

“We are very pleased to be signing another collaboration with MSD, supporting the expansion of the clinical trial program of BT-001, the oncolytic virus expressing our proprietary anti-CTLA-4 antibody, jointly developed by Transgene and BioInvent. It marks a further validation of our expanding and promising clinical pipeline of anti-cancer treatments, which currently encompasses three compounds in four ongoing clinical trials” added Martin Welschof, CEO of BioInvent.

Recruitment in the clinical study is ongoing. The trial is a Phase I/IIa of BT-001, which is being co-developed as part of a 50/50 collaboration between Transgene and BioInvent, as a single agent and in combination with KEYTRUDA for the treatment of solid tumors.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Latest Aithority Insights: Why Contextual Targeting Deserves Another Look with Artificial Intelligence (AI)

[To share your insights with us, please write to sghosh@martechseries.com]

Comments are closed.